Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comparison of antifungal susceptibilities to fluconazole and voriconazole of oral Candida glabrata isolates from head and neck radiation patients.

Literature DB >> 15583322

Comparison of antifungal susceptibilities to fluconazole and voriconazole of oral Candida glabrata isolates from head and neck radiation patients.

A K Burn¹, A W Fothergill, W R Kirkpatrick, B J Coco, T F Patterson, D I McCarthy, M G Rinaldi, S W Redding.

Abstract

The antifungal susceptibilities of 79 oral Candida glabrata isolates to fluconazole and voriconazole were compared. The MICs at which 90% of the isolates tested were inhibited were 1 microg of voriconazole/ml and 32 microg of fluconazole/ml. Oral C. glabrata isolates for which the fluconazole MICs are elevated are commonly those for which the voriconazole MICs are elevated, but these increases may be transient for voriconazole, as they are for fluconazole.

Entities: Chemical Species

Mesh：

Substances：

Year: 2004 PMID： 15583322 PMCID： PMC535272 DOI： 10.1128/JCM.42.12.5846-5848.2004

Source DB: PubMed Journal: J Clin Microbiol ISSN： 0095-1137 Impact factor: 5.948

15 in total

Review 1. Voriconazole: in the treatment of invasive aspergillosis.

Authors: Richard B R Muijsers; Karen L Goa; Lesley J Scott
Journal: Drugs Date: 2002 Impact factor: 9.546

2. Guidelines for treatment of candidiasis.

Authors: Peter G Pappas; John H Rex; Jack D Sobel; Scott G Filler; William E Dismukes; Thomas J Walsh; John E Edwards
Journal: Clin Infect Dis Date: 2003-12-19 Impact factor: 9.079

Review 3. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors: J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal: Clin Infect Dis Date: 1997-02 Impact factor: 9.079

Review 4. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences.

Authors: Dominique Sanglard; Frank C Odds
Journal: Lancet Infect Dis Date: 2002-02 Impact factor: 25.071

5. Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer.

Authors: Spencer W Redding; William R Kirkpatrick; Brent J Coco; Lee Sadkowski; Annette W Fothergill; Michael G Rinaldi; Tony Y Eng; Thomas F Patterson
Journal: J Clin Microbiol Date: 2002-05 Impact factor: 5.948

6. Simple method for detecting fluconazole-resistant yeasts with chromogenic agar.

Authors: T F Patterson; S G Revankar; W R Kirkpatrick; O Dib; A W Fothergill; S W Redding; D A Sutton; M G Rinaldi
Journal: J Clin Microbiol Date: 1996-07 Impact factor: 5.948

7. Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer.

Authors: S W Redding; R C Zellars; W R Kirkpatrick; R K McAtee; M A Caceres; A W Fothergill; J L Lopez-Ribot; C W Bailey; M G Rinaldi; T F Patterson
Journal: J Clin Microbiol Date: 1999-12 Impact factor: 5.948

8. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

Authors: M A Pfaller; S A Messer; R J Hollis; R N Jones; D J Diekema
Journal: Antimicrob Agents Chemother Date: 2002-06 Impact factor: 5.191

Comparison of antifungal susceptibilities to fluconazole and voriconazole of oral Candida glabrata isolates from head and neck radiation patients.

Review 1. Voriconazole: in the treatment of invasive aspergillosis.

2. Guidelines for treatment of candidiasis.

Review 4. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences.

5. Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer.

6. Simple method for detecting fluconazole-resistant yeasts with chromogenic agar.

7. Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer.

8. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

9. Candidal colonization and oral candidiasis in patients undergoing oral and pharyngeal radiation therapy.

10. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.

1. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata.

2. Voriconazole in the management of nosocomial invasive fungal infections.

3. Antifungal suscepitibility profile of candida spp. oral isolates obtained from denture wearers.